Comparing IGF-1 LR3 to its relatives means placing each compound on three axes: how its molecule is built, how long it stays active in circulation, and where it sits on the growth hormone to IGF-1 signaling chain. The honest bottom line comes first: within this family only recombinant human IGF-1 (mecasermin) is an approved drug, and it is cleared for one narrow indication, while IGF-1 LR3, IGF-1 DES, and mechano growth factor are research chemicals with no approved human therapeutic use. Each analog is essentially a different engineered answer to a single question, how much IGF activity escapes the binding proteins and reaches the receptor.
Within the IGF-1 family, only recombinant human IGF-1 (mecasermin) is an approved drug for a narrow indication, while IGF-1 LR3, IGF-1 DES, and MGF are research chemicals with no approved human therapeutic use.
The distinguishing feature is not one change but two, layered onto the native 70-amino-acid IGF-1 sequence, and neither one is aimed at the receptor. An arginine replaces the glutamic acid at position 3 (the R3), and a 13-amino-acid extension is added to the N-terminus (the Long portion), both landing in the region that IGF binding proteins grip. Reported assays put the resulting drop in binding-protein affinity at roughly an order of magnitude, while affinity for the type 1 IGF receptor stays close to native, so what shifts is availability rather than the signal itself.
| Property | Native IGF-1 | IGF-1 LR3 |
|---|---|---|
| Position 3 residue | Glutamic acid | Arginine (R3) |
| N-terminus | Unmodified | 13-residue extension (Long) |
| IGFBP affinity | High | ~10x lower in reported assays |
| Type 1 IGF receptor affinity | Reference | Close to native |
| Free, receptor-available fraction | Small | Much larger |
IGF-1 LR3 differs from native IGF-1 by an arginine-for-glutamate substitution at position 3 and a 13-residue N-terminal extension, changes that lower its IGF-binding-protein affinity by roughly an order of magnitude while leaving type 1 IGF receptor affinity close to native.
The comparison turns on a paradox of binding. Native IGF-1 in the free state has a half-life of only about ten minutes, yet very little of it is ever free: the majority circulates in a ternary complex with IGFBP-3 and the acid-labile subunit, where its measured half-life stretches to roughly twelve to fifteen hours but the peptide is held latent and cannot engage its receptor. IGF-1 LR3 inverts that arrangement by evading the binding proteins, so its reported functional half-life, commonly cited near twenty hours in preclinical descriptions, is spent biologically active rather than in reserve.
Native IGF-1 carries a free half-life of about ten minutes but circulates mostly as a latent twelve-to-fifteen-hour ternary complex, whereas IGF-1 LR3's reported functional half-life of roughly twenty hours in preclinical descriptions is biologically active throughout.
IGF-1 DES(1-3) is native IGF-1 with its first three N-terminal residues removed, and although it shares LR3's broad strategy of dodging the binding proteins, it lands at the opposite end of the spectrum. In tissue and preclinical assays DES appears markedly more potent locally, sometimes cited as several-fold to roughly ten-fold more active, but it is cleared quickly and acts as a sharp local pulse. LR3 trades that peak local intensity for a long, systemic window, and both retain receptor affinity comparable to native IGF-1, so the divergence sits entirely in binding-protein handling and clearance rather than receptor engagement.
| Property | IGF-1 DES(1-3) | IGF-1 LR3 |
|---|---|---|
| Structural change | First 3 N-terminal residues removed | R3 substitution plus 13-residue extension |
| Local potency | Several-fold to ~10x native in assays | Elevated via free fraction, not peak-local |
| Duration | Short-acting, rapidly cleared | Long, sustained systemic window |
| Action shape | Sharp local pulse | Continuous systemic signal |
IGF-1 DES(1-3) is reported in preclinical assays as several-fold to roughly ten-fold more potent locally but is short-acting, while IGF-1 LR3 trades that peak local intensity for a long, systemic window of activity.
Mechano growth factor is not an engineered analog at all but a natural splice variant of the same IGF-1 gene, and that origin drives every difference from LR3. Alternative splicing yields the IGF-1Ec isoform, whose C-terminal E-domain, once cleaved, produces the short MGF peptide expressed in muscle after mechanical loading and damage. Where LR3 is a stable, long-circulating receptor agonist, MGF is thought to act partly through a receptor-independent route and functions as an early, transient pulse that primes muscle satellite cells before handing off to the systemic IGF-1Ea isoform.
Mechano growth factor is a natural IGF-1 splice variant that acts as an early, transient, satellite-cell-priming pulse partly independent of the type 1 IGF receptor, whereas IGF-1 LR3 is an engineered analog producing a continuous, long-circulating receptor signal.
The clearest comparison places these compounds on the somatotropic axis, the regulatory chain running from pituitary to liver to tissues. Growth hormone secretagogues act at the top by prompting the pituitary to release the body's own growth hormone, which then stimulates hepatic and peripheral IGF-1 production, so a secretagogue-driven rise stays inside the axis's self-limiting feedback. IGF-1 LR3 substitutes directly for the downstream effector and sits below every feedback sensor, delivering IGF-receptor activation the axis cannot throttle back and, through that same feedback, potentially suppressing endogenous growth hormone.
Growth hormone secretagogues amplify a self-limiting feedback loop that keeps IGF-1 within a physiological range, whereas IGF-1 LR3 imposes IGF-receptor activation downstream of every feedback sensor that the body cannot moderate.
IGF binding proteins are the control layer that decides how much IGF activity actually reaches receptors, and the analog family is best read as different ways of escaping that control. Six high-affinity IGFBPs bind circulating IGF-1 and IGF-2 with affinity that often exceeds the receptors' own, acting as both carriers and gatekeepers, since bound IGF cannot signal until it is released. Most native IGF-1 is therefore latent in the IGFBP-3 ternary complex, and each engineered analog exists specifically to slip past that gate.
IGF binding proteins hold most native IGF-1 latent in the IGFBP-3 ternary complex, and IGF-1 LR3 and IGF-1 DES both raise potency by evading that buffer, which simultaneously removes the moderation that normally restrains IGF action in tissues.
Risk across this family scales with how much unregulated IGF signaling a compound produces and for how long, which is why the long-acting, systemic analogs attract the most concern. Two hazards apply to any potent IGF agonist: hypoglycemia, because the type 1 IGF receptor is structurally close to the insulin receptor, and proliferative signaling, because IGF-1 is mitogenic and anti-apoptotic, so sustained unbuffered activation raises a theoretical concern about abnormal cell growth. On top of the pharmacology sits a supply-side hazard common to all of them as research chemicals: purity, sequence accuracy, dose, and contamination are genuine unknowns, and no controlled human clinical dosing data exist to establish a safe exposure range.
Risk across these peptides scales with the amount and duration of unregulated IGF signaling, placing the long-acting systemic IGF-1 LR3 at the highest concern for hypoglycemia and proliferative signaling, while no controlled human clinical dosing data exist to establish a safe exposure range for any of them.
On regulatory status the family splits cleanly into one approved drug and a set of unapproved research chemicals. Mecasermin, a recombinant human IGF-1, is cleared for a narrow indication involving severe primary IGF-1 deficiency and short stature, used under prescription with monitoring because of the hypoglycemia and growth-related risks IGF signaling carries. IGF-1 LR3, IGF-1 DES, and MGF have no approved human therapeutic indication anywhere; they are sold as research reagents labeled for laboratory use only, a boundary that keeps them outside the approved-drug framework and the good manufacturing practice standards that govern approved biologics.
Only mecasermin (recombinant human IGF-1) is an approved drug, for a narrow indication under prescription, while IGF-1 LR3, IGF-1 DES, and MGF are unapproved research-use-only reagents that the World Anti-Doping Agency also prohibits as growth factors.
Educational use only. This article describes what the published scientific and clinical literature reports about IGF-1 LR3. It is not medical advice, and it does not recommend, prescribe, or tell anyone to use anything described here. The regulatory status shown at the top of this page reflects what the record showed on the date given there and can change. mdpep.com does not sell any substance described here, does not endorse human use of it, and does not direct anyone to obtain it.
This is not guidance for your situation. Nothing here accounts for your medical history, your current medications, or anything else specific to you, and none of it should be used to make a decision about your own health.
Affiliate disclosure. Some links on this site are affiliate links, and mdpep.com may earn a commission when they are used. That never affects what is written here, it is not an endorsement of any vendor, and it is not a statement that anything described on this page is available to buy.
Every claim here ties to a named primary source and a date, written as plain documentation with nothing for sale. That is how MD PEP covers the whole peptide market.
